Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies.
Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies.
复制标题
长春新碱、放线菌素 D、环磷酰胺化疗可解决对常规疗法耐药的卡萨巴赫-梅里特综合征。
DOI：
10.1111/j.1442-200x.2011.03414.x
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Morikawa Y.
中科院分区：
文献类型：
--
作者：
Fuchimoto Y;Morikawa N;Kuroda T;Hirobe S;Kamagata S;Kumagai M;Matsuoka K;Morikawa Y.
本文介绍了一个病例研究的男性婴儿谁被诊断为Kasabach-Merritt综合征（KMS）后，有大的血管瘤在左臂。各种程序开始，如一线系统治疗使用皮质类固醇和皮下注射，但一直未能提供改善KMS。它提到了长春新碱（VCN）注射液和放线菌素D如何用于降低血小板消耗和输血率。
The article presents a case study of a male infant who was diagnosed with Kasabach-Merritt syndrome (KMS) after having large hemangioma in the left arm. Various procedures were initiated such as first-line systematic therapy using corticosteroids and subcutaneous injection, but has been failed to provide improvements on KMS. It mentions how vincristine (VCN) injections and actinomycin D have been used to decrease the rate of platelet consumption and transfusion.